^
Association details:
Biomarker:FLT3 mutation
Cancer:Acute Myelogenous Leukemia
Drug:azacitidine (DNMT inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Published date:
10/13/2022
Excerpt:
Among patients with NPM1mut, OS and RFS were improved with Oral-AZA by 37% (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.41-0.98) and 45% (HR, 0.55; 95% CI, 0.35-0.84), respectively, vs placebo. Median OS was improved numerically with Oral-AZA among patients with NPM1mut whether without MRD (48.6 months vs 31.4 months with placebo) or with MRD (46.1 months vs 10.0 months with placebo) post-IC. Among patients with FLT3mut, Oral-AZA improved OS and RFS by 37% (HR, 0.63; 95% CI, 0.35-1.12) and 49% (HR, 0.51; 95% CI, 0.27-0.95), respectively, vs placebo.
DOI:
10.1182/blood.2022016293
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study of experimental drug NMS-03592088 in combination with azacitidine in adult patients with blood malignancies Studio del farmaco sperimentale NMS-03592088 in combinazione con azacitidina in pazienti adulti con tumori maligni del sangue

Excerpt:
...Fase I:• Tossicità limitanti della dose (dose limiting toxicity, DLT) al primo ciclo;Fase II:• LMA con FLT3-mutato: Tasso di Remissione Completa Composita (CRc: CR +CRi), cioè Remissione Completa (CR)+ Remissione Completa con recupero ematologico incompleto (CRi), come determinato dagli Sperimentatori sulla base delle raccomandazioni European LeukemiaNet (ELN) del 2017.• LMMC: Tasso di Risposta Globale, cioè Risposta Completa (CR) + Remissione citogenetica completa (CCR) + Remissione Parziale (PR) + Risposta Midollare (MR) + Beneficio Clinico (CB) come definito dai criteri dell'International Working Group (IWG) specifici della malattia....
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Azacitidine and Venetoclax in Treating Patients With High Risk Acute Myeloid Leukemia in Remission

Excerpt:
...FLT3 mutation, history of antecedent hematologic disorder (AHD), presence of dysplasia in the bone marrow, therapy-related AML, history of requiring more than 1 cycle of intensive induction chemotherapy to achieve first remission, or presence of persistent minimal residual disease (detected by cytogenetics, molecular markers, or flow cytometry) at any point after initial induction cycle....
More C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Published date:
11/04/2021
Excerpt:
In QUAZAR AML-001, pts aged ≥55 years with AML and NCCN intermediate or poor-risk cytogenetics at Dx were randomized 1:1 to receive Oral-AZA 300 mg or PBO QD within 4 mo after attaining first CR/CRi with IC (induction ± consolidation)....In MV analyses, Oral-AZA significantly improved OS vs PBO when adjusted for other variables (P = 0.035); NPM1 status (P = 0.001), FLT3 status (P = 0.035), and cytogenetic risk at Dx (P < 0.001) were each also significantly predictive of OS, as was post-IC MRD status (P < 0.001).
DOI:
10.1182/blood-2021-147465